Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 515

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Donepezil for dementia due to Alzheimer's disease

Open access
Birks, JS, Harvey, R · 2003 · Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Alzheimer's disease is the most common cause of dementia and is a primary degenerative disease of the brain of unknown cause. Onset is usually late in life with increasing impairment of memory, developing gradually into a global impairment of cognition, orientation, linguistic ability and judgement. The clinical course is accompanied by growing disability and dependency on care. One of the characteristic features of the disease is the widely variable rate of progression seen in different patients. Acetylcholine is an important neurotransmitter associated with memory, and abnormalities in cholinergic neurones (including cell loss) are among the many neurological and neurochemical abnormalities that develop in AD. One approach to lessening the impact of these abnormalities is to inhibit the breakdown of acetylcholine by blocking the relevant enzyme. Tacrine was the first compound approved as a treatment for AD in the US and worked in this way, but caused severe side effects. E2020 (donepezil, Aricept) is a second generation cholinesterase inhibitor and appears to be highly specific, with relatively few side effects. OBJECTIVES: The objective of this review is to assess whether or not donepezil improves the well-being of patients with mild or moderate Alzheimer's disease. SEARCH STRATEGY: The Cochrane Dementia and Cognitive Impairment Group Register of Clinical Trials, was searched using the terms 'donepezil', 'E2020' and 'ARICEPT'. Medline, PsychLIT and EMBASE electronic databases were searched with the above terms. Members of the Donepezil Study Group and Eisai Inc were contacted. SELECTION CRITERIA: All unconfounded, double-blind, randomised controlled trials in which treatment with donepezil was administered for more than a day and compared with placebo in patients with Alzheimer's disease. DATA COLLECTION AND ANALYSIS: Data were extracted independently by the reviewers (JSB & DB), pooled where appropriate and possible, and the weighted or standardised mean differences or Peto odds ratios (95%CI) estimated. Where possible, intention-to-treat data were used. MAIN RESULTS: There are 4 included trials, covering treatment of 12 or 24 weeks duration in highly selected patients. The only information available on one trial (Gauthier 1998) is a conference abstract which reports no usable results. Available outcome data cover domains including cognitive function and global clinical state, but data on several important dimensions of outcome are not available. The results of three trials suggest a small beneficial effect of donepezil in improving cognitive function: at a 5mg/day dose, improvements measured -2.6 points (95%CI -3.5 -- -1.8) on weighted mean difference, in the midrange of the 70 point ADAS-Cog scale. The results of two trials show some improvement in global clinical state (assessed by an independent clinician) in those treated with donepezil compared to placebo. The patient's own rating of their Quality of Life showed no benefit of donepezil compared with placebo. There were significantly more withdrawals before the end of treatment from the 10mg/d (but not the 5mg/d) donepezil group compared with placebo, which may have resulted in some overestimation of beneficial changes at 10mg/d in progressively declining characteristics, as last available measures were used in analyses. A variety of adverse effects were recorded, but very few patients left a trial as a direct result of the intervention. REVIEWER'S CONCLUSIONS: In selected patients with mild or moderate Alzheimer's disease treated for periods of 12 or 24 weeks, donepezil produced modest improvements in cognitive function and study clinicians rated global clinical state more positively in treated patients. No improvements were present on patient self-assessed quality of life and data on many important outcomes are not available. The practical importance of these changes to patients and carers is unclear.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd001190

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 72

  1. Homma, 1998, Late phase II clinical study of acetyl cholinesterase inhibitor E2020 in patients with Alzheimer-type dementia, Clinical Evaluation, 26, 251
  2. Friedhoff LT Ieni JR Rogers SL Pratt RD Donepezil provides long-term clinical benefits for patients with Alzheimer's Disease Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum;1998 Jul 12-16, Glasgow, Scotland 1998 ABSTRACT REF: PW11017 SR-HANDSRCH
  3. Friedhoff LT Rogers SL Correlation between the clinical efficacy of donepezil HCL (E2020) and red blood cell (RBC) Acetylcholinesterase (ACHE) inhibition in patients with Alzheimer's disease Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 Mar 5-8, San Diego 1997 6 7
  4. Rogers SL Friedhoff LT E2020 improves cognition and quality of life in patients with mild to moderate Alzheimers Disease: results of a phase II trial Proceedings of the 46th Annual meeting of the American Academy of Neurology. 1994 May 1-7, Washington DC 1994 A165
  5. 1996, The Efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomised, double-blind, placebo-controlled trial, Dementia, 7, 293
  6. Pratt, 1999, Long-term safety and tolerability of donepezil: results from a phase iii extension trial of patients with mild to moderately severe alzheimer's disease, European Journal of Neurology, 6, 116
  7. 2001, Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease, Archives of Neurology, 58, 427, 10.1001/archneur.58.3.427 · DOI · Paper page
  8. Friedhoff, 1997, Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease - results of a preliminary evaluation. presented at the annual meeting of the American Academy of Neurology. Boston, Neurology, 48, A100
  9. Friedhoff, 1997, Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis, Eur J Neurology, 4, Suppl 1, S9
  10. Rogers, 1996, E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: Results of a 30-week phase III trial, Neurology, 46, A217 S14.001 AR
  11. Rogers SL Mohs RC Friedhoff LT Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from Phase III trials American Psychiatric Association 150th Annual Meeting, San Diego 1997 · DOI
  12. Bayer AJ, Rossor M, Hecker J, Gauthier S, Burns A, Petite H, Moller HJ, Rogers SL, Friedhoff LT, International Donepezil Study Group Donepezil improves functional activity in patients with Alzheimer's disease Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum; 1998 Jul 12-16, Glasgow, Scotland 1998 SR-HANDSRCH
  13. Gauthier S Rosser M Hecker J Petite H Rogers S Mohr E Burns A Friedhoff LT Rogers S Donepezil Produces Both Clinical Global and Cognitive Test Improvement in Patients with Alzheimer's Disease Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4, Toronto, Canada 1998 SR-HANDSRCH
  14. Gauthier S Rossor M Hecker J Results from a multinational Phase III clinical trial of donepezil in Alzheimer's disease [abstract] [poster presentation at 5th International Geneva/Springfield Symposium on Advances in Alzheimer therapy]
  15. Tariot P Cummings JL Katz IR Perdomo CA Whalen E Sovel MA Schwam EM Donepezil was well-tolerated and enhanced cognition in nursing home patients with alzheimer's disease Journal of the American Geriatrics Society 1999 S3
  16. Mohs R Doody R Morris J Ieni J Rogers S Perdomo C Pratt R Donepezil preserves functional status and improves cognition in alzheimer's disease patients: results from a 1-year propective placebo-controlled study Journal of the American Geriatrics Society 2000 S46 · DOI
  17. Mohs, 1999, Donepezil preserves functional status in Alzheimer's disease patients: results from a 1-year prospective placebo-controlled attrition study, Journal of the European College of Neuropsychopharmacology, 9, S328, 10.1016/S0924-977X(99)80460-X · DOI
  18. Mohs R Doody R Morris J Ieni JR Rogers SL Perdomo CA Pratt RD Donepezil preserves functional status in Alzheimer's disease patients: results from a 1-year prospective placebo-controlled study Proceedings of the Quality Research in Dementia Conference; 2000 Nov 19-22, London 2000 · DOI
  19. Mohs RC Doody RS Morris JC Ieni JR Rogers SL Perdomo CA Pratt RD A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients Neurology 2001 481 8 · DOI · Paper page
  20. Mohs RC Doody RS Morris JC Leni JR Rogers SL Perdomo CA Pratt RD Donepezil preserves functional status in Alzheimer's disease Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18, Chicago, Illionois 2000 SR-HANDSRCH
  21. Pratt R Mohs R Doody R Morris J Rogers S Ieni J Perdomo C Donepezil preserves functional status in Alzheimer's disease patients results from a 1-year prospective placebo controlled functional study Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5-8, 2000; Stockholm, Sweden 2000 178 · DOI
  22. Lendon CL Determination of respones to anticholinesterase therapy in the treatment of Alzheimer's disaese The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 1287
  23. Robert P, Lebert F, Goni S, Touchon J, Vincent S, ARIAL Study Investigators Collaborative Group The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease Proceedings of the Quality Research in Dementia; 19-22 November, 2000; London 2000
  24. Robert PH, Lebert F, Goni S, Touchon J, ARIAL Study Investigators Collaborative Group The impact of caregiver distress of donepezil treatment of patients with mild alzheimer's disease Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20, Washington DC 1999 SR-HANDSRCH
  25. Feldman H Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of alzheimer's disease Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm 2000 59
  26. Feldman H Gauthier S Hecker J Vellas B Subbiah P Whalen E Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe alzheimer's disease Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm 2000 174 · DOI
  27. Gauthier S Feldman H Vellas B Subbiah P Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe alzheimer's disease Journal of the American Geriatrics Society 2000 S2
  28. Mastey V Wimo A Winblad B Haglund A Jacobson L Miceli R Zhang R Subbiah P Donepezil reduces the time caregivers spend providing care: results of a one-year, double-blind, randomized trial in patients with mild to moderate Alzheimer's disease Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco 2001
  29. Soininen H, Winblad B, Engedal K, Verhey F, Waldemar G, Wimo A, Zhang R, Subbiah P, Donepezil Nordic Study Group Response to Donepezil is not predicted by apolipoprotein E genotype and/or gender Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington 2000 · DOI
  30. Wimo A Winblad B Mastey V An economic evaluation of Donepezil in mild to moderate Alzheimers Disease: Results of a one-year, double-blind, randomized trial Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington DC 2000 · DOI
  31. Wimo A Winblad B Mastey V Haglund A Hertzman P Miceli R Jacobson L Subbiah P An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one-year, double-blind, randomized trial Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18, Chicago, Illionois 2000 SR-HANDSRCH · DOI
  32. Winblad B Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with alzheimer's disease Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm 2000 164
  33. Winblad, 1999, Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one-year, double-blind trial in patients with mild to moderate Alzheimer's disease, International Psychogeriatrics, 11, 138
  34. Winblad B Engedal K Soininen H Verhey F Waldemar G Wimo A Wetterholm AL Zhang R Haglund A Subbiah P Donepezil enhances global function and acitivities of daily living compared with placebo in a one-year, double-blind trial in patients with mild to moderate alzheimer's disease Proceedings of the Quality Research in Dementia Conference; 2000 Nov 19-22, London 2000
  35. Friedhoff, 1999, Donepezil provides long term benefits for patients with Alzheimer's disease, International Journal of Psychopharmacology, 2, 5175(PW11017)
  36. Rogers, 1995, Clinical benefits are maintained during long-term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor E2020, European Journal of Neuropsychopharmacology, 5, 386, 10.1016/0924-977X(95)90701-E · DOI
  37. Ames D Boada M Sakka P Triau E Turcani P Vagenas V Bahra R Zhang R Efficacy and tolerability of donepezil in patients with alzheimer's disease: findings from a large multinational experience study Proceedings of the 17th Alzheimer's Disease International Conference; 2001 Oct 25-27, Christchurch, New Zealand 2001 181
  38. Birt AR Fay S Graham JE Rockwood K Recovery of intention as a noverl effect on traeting Alzheimer's disease with donepezil The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 595
  39. Boundy K, Brodaty H, Australian Donepezil Study Group, Barrington M, O'Leary M, Short K, Bahra R, Zhang R Eficacy of donepezil in patients with alzheimer's disease: findings from the autralian subset of a large multinational experience study Proceedings of the 17th Alzheimer's Disease International Conference; 2001 Oct 25-27, Christchurch, New Zealand 2001
  40. Bullock R Passmore F Potocnik F Hock C The tolerability, ease of use and efficacy of donepezil and rivastigmine in alzeimer's disease patients: a 12-week, multinational, comparative study Journal of the American Geriatrics Society 2001 S19
  41. Potocnik FC Smith R Passmore P Hock C Wilkinson D Maud CM Hopker S Tolerability, ease of use, and efficacy of donepezil and rivastigmine in alzheimer's disease patients Proceedings of the Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans 2001 · DOI
  42. Wilkinson D Passmore P Potocnik F Maud C Hock C Donepezil compared to rivastigmine in Alzheimer's disease: similar efficacy but better tolerability and physician and caregiver satisfaction in a multinational randomized trial Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco 2001 · DOI
  43. Clary C McRae T Griesing T Whalen E The safety of donepezil and sertraline for the management of behavioral symptoms in patients with Alzheimer's disease International Journal of Neuropsychopharmacology 2000 S267 SR-HANDSRCH
  44. Finkel S McRae T Burt T Sertraline and donepezil demonstrate greater efficacy and similar tolerability compared to donepezil alone in non-depressed patients with Alzheimer's disease Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco 2001
  45. Fillit H Hill JW Futtertman R Mastery V Sustained donepezil therapy reduces healthcare costs in Alzheimer's disease The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 192
  46. Hampel H Berger F Froelich L Switching from other antidementive therapies to donepezil (aricept ® ): improvement of quality of life of alzheimer patients in routine clinical use The International Symposium on advances in Alzheimer therapy, 2002, geneva 2002 198 · doi:10.1016/s0924-977x(02)80625-3
  47. Homma, 1998, Late phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia, Clinical Evaluation, 26, 185
  48. Homma, 1998, Late phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia, Clinical Evaluation, 26, 209
  49. Imai, 1998, Early phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia, Clinical Evaluation, 26, 145
  50. Imai, 1998, Early phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia, Clinical Evaluation, 26, 165
  51. Imai, 1998, Late phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia, Clinical Evaluation, 26, 233
  52. Kauffer D Catt K Pollock B DeKosky S Assessing the effects of donepezil in alzheimer's patients and its impact on caregivers Journal of the American Geriatrics Society 1998 S66
  53. Leube D Grodd W Erb M Henning W Bartels M Kircher T Task related cortical areas are differentially activated in pateints with Alzheimers' disease after a ten week treatment with donezepil The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 1548
  54. Maltz J Eberling J Jagust w Budinger T Donepezil therapy enhancse methacholine induced cutaneous vasodilation in Alzheimer's disease patients The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 318
  55. McRae T Orazem J A large, community-based trial of donepezil in the treatment of alzheimer's disease (AD) Journal of the American Geriatrics Society 1999 S63
  56. McRae T Knopman D Duttagupta S Ieni J Provenzano G Donepezil delays time to nursing home placement in patients with Alzheimer's disease Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco 2001 · doi:10.1046/j.1524-4733.2001.40202-235.x
  57. McRae T Knopman D Mastey V Ieni J Provenzano G Donepezil is strongly associated with delayed nursing home placement in patients with alzheimer's disease Journal of Neuroscience 2001 S536
  58. Mega M Dinov I Manese M Felix J O'Connor S Toga A Cummings J Cerebral metabolic activation with cholinesterase inhibitor therapy in Alzheimer's disease The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 430
  59. Peng D Xu X Hou Q The safety and efficacy of aricept in patients with alzheimer disease Chinese Journal of Neurology 2002 19 21
  60. Rockwood K Graham J Fay S Translating from regulatory measures to patients' daily lives an analysis of alzheimer's disease treatment with donepezil The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 2034
  61. Shua-Haim J Smith J Amin S Shua-Haim V Comparison of combinition therapy with rivastigmine exelon and donepezil aricept versus rivastigmine alone for treatment of Alzheimer's disease safety tolerability and clinical experiance after one year of treatment a cross section study The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 292
  62. Shua-Haim J Smith J Potel S A head to study of donepezitl aricept rivastigmine exlon and galantamine reminyl for the treatment of Alzheimer's disease safety tolerability clinical and caregiver impression after 4-5 months of trratment a prospective study The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 286
  63. Tsolaki M Gerothanassis D Aristotle CP Efficacy and safety of cholinesterase inhibitors a longitudinal comparative study between donepezil and rivastigmine The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 2038
  64. Werber EA Klein C Rabey MJ Evaluation of cholinergic treatment in demented by p300 evoked related potentials The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 442
  65. Anon Double-blind trial will compare two anti-alzheimer's drugs Journal of Dementia Care 2001 6
  66. Johannsen P, Barcikowska M, Hasselbalch S, Ihl R, Karageorgiou C, Nunez M, Salmon E, Trixler M, Qvitzau S, Johansen L, Emir B, Subbiah P, The AWARE Study Group Results from the pre-randomization phase of the donepezil aware study further understanding the meaning of clinical benefit Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva 2002 201
  67. Gauthier S Lussier I Donepezil treatment is associated with alleviation of caregiver burden in alzheimer's disease: interim results from an open-label multicentre clinical trial European Journal of Neurology 1999 116 SR-HANDSRCH
  68. 1987, Diagnostic and Statistical Manual of Mental Disorders
  69. Berg, 1988, Clinical Dementia Rating (CDR), Psychopharm Bull, 24, 637
  70. Homma, 1991, Development of a new rating scale for dementia in the elderly: Mental Function Impairment Scale (MENFIS), Journal of Geriatric Psychiatry, 2, 1217
  71. 1992, The ICD-10 classification of mental and behavioural disorders: clinical description and diagnostic guidelines
  72. Mulrow, 1997, Cochrane Collaboration Handbook [updated 9 December 1996].

Cited by

See all 515

Metadata

Authors
Birks, J., & Harvey, R.
Venue
Cochrane Database of Systematic Reviews
Published
2003-07-21
Issue
2
Pages
CD001190-CD001190
ISSN
1361-6137 (ISSN-L)
OpenAlex
W1551599804
Cited by
515
References
69
Type
reference entry
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.